KRKA Slovensko
Generic prescription, over-the-counter and veterinary medicines sold in Slovakia by the local unit of a foreign pharma group
Highlights
- ProfitableFY2025 net profit €285k · RÚZ
About KRKA Slovensko
KRKA Slovensko, s. r. o. is the Slovak subsidiary of a foreign generic pharmaceutical group. The website, which presents the wider Krka group, describes its activity as development, manufacturing, marketing and sale of prescription medicines, over-the-counter medicines and veterinary medicines.
The company's product range is presented as a portfolio of generic medicines for common conditions, including treatments for metabolic, oncological, infectious and urogenital diseases, plus vitamins and minerals. The website is addressed to patients and healthcare professionals and runs KRKA MED, a professional medical content portal. The website does not describe the Slovak entity's distribution channels or revenue split.
The company has operated on the Slovak market for more than 20 years and is registered in Bratislava, founded in 2008. The group figures on the website (over 13,000 employees, products in more than 70 countries) refer to the whole group, not the Slovak entity alone. The careers page says the group is seeking pharmacists, chemists, physicians, veterinarians, economists and marketers for key positions.
Product: Prescription medicines, over-the-counter medicines and veterinary medicines from a generic portfolio of about 250 active substances, as listed on the product page.
Financials
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | €8.8M | €8.4M | €8.7M | €7.6M | €6.5M |
| Growth | +5% | −3% | +15% | +17% | — |
| EBITDA | €608k | €583k | €718k | €550k | €498k |
| Operating profit | €416k | €396k | €410k | €356k | €307k |
| Net profit | €285k | €275k | €290k | €271k | €214k |
| Net margin | 3.2% | 3.3% | 3.3% | 3.6% | 3.3% |
| Personnel costs | €4.0M | €3.7M | €3.9M | €3.6M | €3.1M |
| Total assets | €3.7M | €3.9M | €3.4M | €3.1M | €2.8M |
| Cash | €429k | €69k | €34k | €66k | €25k |
| Liabilities | €1.1M | €1.0M | €816k | €829k | €817k |
| Equity | €2.6M | €2.8M | €2.6M | €2.3M | €2.0M |
As filed with RÚZ (Slovak register of financial statements). Each year links to its statement.
Jobs at KRKA Slovensko
Leadership
- Marjan Vrbnjak · Konateľ (Managing director)Source: business register
More biotech & pharma companies
MagnaPharm SK
Pharmaceutical import, local distribution and support services for manufacturers and customers in SlovakiaProfitableGrowingNew on EvolcMediXbank, n.o.
Nonprofit biomedical research and biobanking for researchers and healthcare professionalsNew on EvolcMGP
Distributes radiopharmaceuticals, contrast agents and radiation sources to healthcare, research and industry in Czechia and SlovakiaNew on EvolcMIKROCHEM
Pharmaceutical and chemical manufacturing and R&D services for pharmaceutical and chemical companiesMINITÜB SLOVAKIA
Assisted reproduction systems for animal insemination and embryo transfer, also used in human fertility treatmentProfitableMultiplexDX
Cancer diagnostics, molecular testing, and research services for healthcare and life-science organizationsGrowing
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Tag ManagerMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Frontend frameworks
- NuxtHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Website resourcedeclared script/iframe or software asset
- Website resourcedeclared script/iframe or software asset
- VueMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
- Page markupsoftware structure signature
- Page markupsoftware structure signature
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.